source
- Amgen ends $500M Crohn’s disease collaboration with TScan, but TScan says pipeline strategy stays on trackAmgen has terminated its collaboration with TScan Therapeutics that was aimed at Crohn’s disease, ending a deal that could have delivered up to $500 million in milestones. The partnership began in…
- BioMarin to acquire Alesta Therapeutics for $275 million to expand bone disease pipelineBioMarin Pharmaceutical announced it will purchase Alesta Therapeutics for an upfront payment of $275 million. Alesta is developing an oral small-molecule drug, ALE1, aimed at treating hypophospha…